標(biāo)題: Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir [打印本頁] 作者: 喝水 時(shí)間: 2025-3-21 16:49
書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)
書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)學(xué)科排名
書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度
書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱HCV: The Journey from Discovery to a Cure被引頻次
書目名稱HCV: The Journey from Discovery to a Cure被引頻次學(xué)科排名
書目名稱HCV: The Journey from Discovery to a Cure年度引用
書目名稱HCV: The Journey from Discovery to a Cure年度引用學(xué)科排名
書目名稱HCV: The Journey from Discovery to a Cure讀者反饋
書目名稱HCV: The Journey from Discovery to a Cure讀者反饋學(xué)科排名
作者: Diastole 時(shí)間: 2025-3-22 00:19 作者: KEGEL 時(shí)間: 2025-3-22 01:00 作者: 詩集 時(shí)間: 2025-3-22 04:50
https://doi.org/10.1057/9781137339096hepatocellular carcinoma. The HCV genome was cloned molecularly in 1989, and around 25?years later, antiviral therapy has been established that eliminates the virus in more than 95% of infected individuals. To reach this goal, several hurdles had to be overcome, a major one having been the developme作者: reflection 時(shí)間: 2025-3-22 11:04 作者: 隱語 時(shí)間: 2025-3-22 15:27 作者: 率直 時(shí)間: 2025-3-22 18:53
The Chinese Path Toward a Leaner Governmenteffort on the discovery and development of interferon (IFN)-free therapies that are well tolerated and have increased cure rates. This chapter describes the discovery and development of sofosbuvir, the first live-targeting prodrug of a nucleotide analog, and contains a detailed overview of the synth作者: 分期付款 時(shí)間: 2025-3-23 00:01
A Modified Vision of Divine Determination, The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.作者: 柔軟 時(shí)間: 2025-3-23 05:26
HJD-04: The Chinese-Developed Systemass of indolobenzazepines. Within this research, a strategic decision to abandon a highly potent but physiochemically problematic series in favor of one of lower molecular weight and potency was key in the realization of the program’s objectives. Subsequent cycles of analog design incorporating prog作者: 反復(fù)拉緊 時(shí)間: 2025-3-23 07:13 作者: 松雞 時(shí)間: 2025-3-23 13:10
and ribavirin (R) which was associated with a low success rate in patients with the most common genotype 1 hepatitis C virus (HCV) infection (40–50%), significant treatment-limiting side effects, and a long (48-week) duration of treatment. The HCV protease inhibitor telaprevir (VX-950) was discover作者: avenge 時(shí)間: 2025-3-23 14:27
Yuwei Sun,Zheng Zheng,Huiyan Dongiviral agents, the only treatment option was a regimen of interferon and ribavirin. It was modestly effective with only ~40% of genotype 1 patients demonstrating sustained virologic response. It was also accompanied with severe side effects with flu-like symptoms and increased suicidal tendencies du作者: 百科全書 時(shí)間: 2025-3-23 20:48
The Chinese Stock Market Volume IIse that was explored in the context of tripeptide carboxylic acid-based inhibitors. A cyclopropyl-acyl sulfonamide moiety was found to be the optimal element at the P.-P.’ interface enhancing the potency of carboxylic acid-based prototypes by 10- to >100-fold, dependent upon the specific background.作者: 別炫耀 時(shí)間: 2025-3-24 01:28 作者: 有說服力 時(shí)間: 2025-3-24 06:26
International Organization for Migrationt of this disease, offering patients an excellent chance for a complete cure. Starting from inhibitors incorporating oxime-based P*-shelf moieties, a collaborative effort between Abbott Laboratories and Enanta Pharmaceuticals generated ABT-450 (paritaprevir, a component of Technivie? and Viekira Pak作者: 共同給與 時(shí)間: 2025-3-24 09:22 作者: bromide 時(shí)間: 2025-3-24 14:22
From B to Non-B to C: The Hepatitis C Virus in Historical Perspectivesurface protein of the hepatitis B virus (HBV) and the first marker for any human hepatitis virus. Studies of transfusion-associated hepatitis made it evident that most cases were unrelated to HBV. The later discovery of the hepatitis A virus (HAV) made it apparent that non-B cases were also non-A l作者: Increment 時(shí)間: 2025-3-24 18:29 作者: 外露 時(shí)間: 2025-3-24 22:46 作者: Recessive 時(shí)間: 2025-3-24 23:46
The Hepatitis C Virus Replicon System and Its Role in Drug Developmenthepatocellular carcinoma. The HCV genome was cloned molecularly in 1989, and around 25?years later, antiviral therapy has been established that eliminates the virus in more than 95% of infected individuals. To reach this goal, several hurdles had to be overcome, a major one having been the developme作者: tendinitis 時(shí)間: 2025-3-25 04:51
The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infectionkines that are an essential part of the body’s natural response to viral pathogens. In 1991, interferon-α (IFN-α) injections were first approved by the Food and Drug Administration for the treatment of HCV infection and remained the backbone of therapy until late 2014. As monotherapy, IFN-α injected作者: 臥虎藏龍 時(shí)間: 2025-3-25 10:30
Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitorsive anti-HCV activity in a cell-based HCV replicon assay and, as their triphosphates, inhibited HCV NS5B polymerase enzyme in a cell-free assay. Since then, a number of new 2′-modified nucleoside analogs and nucleotide derivatives were synthesized and evaluated for direct inhibition of HCV replicati作者: Insulin 時(shí)間: 2025-3-25 11:57 作者: Eeg332 時(shí)間: 2025-3-25 18:02 作者: 馬具 時(shí)間: 2025-3-25 21:07
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymeraseass of indolobenzazepines. Within this research, a strategic decision to abandon a highly potent but physiochemically problematic series in favor of one of lower molecular weight and potency was key in the realization of the program’s objectives. Subsequent cycles of analog design incorporating prog作者: 鐵塔等 時(shí)間: 2025-3-26 04:01
Evolution of HCV NS3/4a Protease Inhibitorsting point for medicinal chemistry. However, their less-than-ideal properties as leads would make the path to orally bioavailable inhibitors a highly challenging one. Extensive optimization efforts by multiple groups led to inhibitors with reduced peptidic character in both reversible and slowly rev作者: 你正派 時(shí)間: 2025-3-26 06:01
Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor and ribavirin (R) which was associated with a low success rate in patients with the most common genotype 1 hepatitis C virus (HCV) infection (40–50%), significant treatment-limiting side effects, and a long (48-week) duration of treatment. The HCV protease inhibitor telaprevir (VX-950) was discover作者: Factorable 時(shí)間: 2025-3-26 08:30
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1iviral agents, the only treatment option was a regimen of interferon and ribavirin. It was modestly effective with only ~40% of genotype 1 patients demonstrating sustained virologic response. It was also accompanied with severe side effects with flu-like symptoms and increased suicidal tendencies du作者: 娘娘腔 時(shí)間: 2025-3-26 14:43 作者: Trypsin 時(shí)間: 2025-3-26 20:33 作者: Truculent 時(shí)間: 2025-3-27 01:00
The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevirt of this disease, offering patients an excellent chance for a complete cure. Starting from inhibitors incorporating oxime-based P*-shelf moieties, a collaborative effort between Abbott Laboratories and Enanta Pharmaceuticals generated ABT-450 (paritaprevir, a component of Technivie? and Viekira Pak作者: 裹住 時(shí)間: 2025-3-27 03:13
Discovery and Development of the Next-Generation HCV NS3 Protease Inhibitor Glecaprevirs a component of two FDA-approved IFN-free DAA combination therapies (Viekira Pak? and Technivie?) with approval to treat genotypes 1 and 4, respectively. However, its activity against some key resistant mutants and other HCV genotypes was limited. This chapter reviews our further effort to identify作者: 同位素 時(shí)間: 2025-3-27 07:57
https://doi.org/10.1057/9781137339096nt of robust cell culture systems that were suitable for drug development, but also to study the individual steps of the HCV replication cycle. Here we summarize the step-by-step establishment of HCV cell culture systems with a focus on the replicon system that played a major role in the development of HCV-specific direct-acting antiviral drugs.作者: 剝削 時(shí)間: 2025-3-27 10:53 作者: 欄桿 時(shí)間: 2025-3-27 13:38 作者: Hypopnea 時(shí)間: 2025-3-27 18:36 作者: 闡明 時(shí)間: 2025-3-27 22:18
Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitorson. Potency, selectivity, and other drug-like properties were substantially optimized, and consequently more than a dozen compounds were advanced into preclinical and clinical evaluations. In the end, a prodrug of 2′-fluoro-2′-.-methyluridine monophosphate PSI-7977 (GS-7977, sofosbuvir) was approved for the treatment of chronic HCV infection.作者: 處理 時(shí)間: 2025-3-28 05:44
The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir?), incorporating novel P*-phenanthridine and P3-amide capping groups and pharmacokinetically boosted by ritonavir. The discovery and development of ABT-450 enabled one of the first IFN-free combination therapies for HCV genotype 1 infection and contributed to the transformation of the treatment of this chronic and deadly disease.作者: Entrancing 時(shí)間: 2025-3-28 09:00
1862-2461 of HCV research that contributed to the development of key dHepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, an作者: leniency 時(shí)間: 2025-3-28 11:28
Book 2019 major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting ant作者: 呼吸 時(shí)間: 2025-3-28 14:41 作者: Aspirin 時(shí)間: 2025-3-28 20:26
HCV: The Journey from Discovery to a Cure978-3-030-28207-3Series ISSN 1862-2461 Series E-ISSN 1862-247X 作者: Libido 時(shí)間: 2025-3-29 01:46 作者: 怎樣才咆哮 時(shí)間: 2025-3-29 06:28
Topics in Medicinal Chemistryhttp://image.papertrans.cn/h/image/420175.jpg作者: 聾子 時(shí)間: 2025-3-29 09:12
A Modified Vision of Divine Determination, The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.作者: 機(jī)警 時(shí)間: 2025-3-29 13:15
Evolution of HCV NS5B Non-nucleoside Inhibitors The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.作者: Morphine 時(shí)間: 2025-3-29 16:50 作者: 實(shí)施生效 時(shí)間: 2025-3-29 22:14
From B to Non-B to C: The Hepatitis C Virus in Historical Perspectivety. The major breakthrough occurred in the late 1980s when the Chiron Corporation cloned the NANBH agent and renamed it the hepatitis C virus (HCV). Adding HCV serologic testing, and later molecular testing, to routine donor screening virtually eradicated TAH with current risk estimated to be one ca作者: 大笑 時(shí)間: 2025-3-30 01:49 作者: 令人發(fā)膩 時(shí)間: 2025-3-30 06:38
HCV Molecular Virology and Animal Modelsnstitute the current anti-HCV regimens with cure rates of above 95%. This chapter is divided into two parts. The first part begins with a short introduction to HCV and its life cycle and reviews insights into biochemical and functional characteristics of HCV RNA elements and proteins. The second par作者: 倫理學(xué) 時(shí)間: 2025-3-30 09:00
The Role of Interferon for the Treatment of Chronic Hepatitis C Virus InfectionN-α). While this reduced the need for subcutaneous injections from three times a week to once a week which improved patients’ adherence, the increase in SVR with PegIFN-α over standard IFN-α was relatively modest. Further, drug-related side effects remained problematic, limiting HCV treatment uptake作者: conceal 時(shí)間: 2025-3-30 16:17 作者: magenta 時(shí)間: 2025-3-30 17:35
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerasemplex inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir in a single, fixed-dose formulation (Ximency) resulted in the approval by the Japanese Pharmaceutical and Food Safety Bureau for its use in the treatment of patients infected with genotype 1 HCV.作者: 臆斷 時(shí)間: 2025-3-31 00:12 作者: Lumbar-Spine 時(shí)間: 2025-3-31 04:04 作者: TIA742 時(shí)間: 2025-3-31 08:04
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1e compound libraries did not result in any starting point for SAR optimization. Introduction of electrophilic traps to natural substrate of the enzyme identified a ketoamide-derived undecapeptide lead. It was optimized to identify the first ketoamide-derived direct-acting antiviral agent for the tre作者: 子女 時(shí)間: 2025-3-31 09:47
